NTx Bio Platform Supports Personalized mRNA Vaccine Manufacturing for Phase 1 Melanoma Trial NTx Bio, a company developing next-generation biomanufacturing technologies, announced that its NTxscribe® CORE platform is being used…
Tolerance Bio Licenses Efineptakin Alfa From NeoImmuneTech to Advance Thymus-Targeted Therapies Tolerance Bio, Inc., a biotechnology company focused on preserving, regenerating, and modulating thymic function to address immune-related diseases and…
Regenerative Research Foundation Selected as a Winner of NIH’s Complement-ARIE Challenge The Regenerative Research Foundation has announced that its Neural Stem Cell Institute (NSCI) has been selected as a Phase…
Merck and Moderna Report Positive Phase 3 Results for Personalized mRNA Cancer Therapy in Melanoma Merck, known as MSD outside the United States and Canada, and Moderna, Inc. have announced…
BioTalent Canada and Montréal InVivo Strengthen Partnership to Expand Life Sciences Workforce Development BioTalent Canada and Montréal InVivo have announced an expanded partnership designed to strengthen workforce development across Canada’s…
BeOne Medicines, BeOne Care Foundation and The Max Foundation Renew Partnership to Expand BRUKINSA Access for Patients With CLL BeOne Medicines Ltd., a global oncology company, has announced the renewal…
VectorBuilder and Lir Therapeutics Partner to Develop Scalable, AI-Engineered AAV Capsids for Gene Therapy VectorBuilder, a global provider of gene delivery technologies, and Lir Therapeutics, a biotechnology company focused on…
Cardio Diagnostics Launches In-House CLIA-Certified Laboratory to Advance Precision Cardiovascular Testing Cardio Diagnostics Holdings, Inc., an artificial intelligence-driven precision cardiovascular medicine company, has announced the official launch of its new…
bioAffinity Technologies Expands Government Healthcare Reach Through Distribution Agreement with AvMEDICAL for CyPath Lung bioAffinity Technologies, Inc., a biotechnology company focused on developing noninvasive diagnostic solutions for the early detection…
Enveda Reports Positive Phase 1 Results for ENV-308, an Oral Therapy Designed to Support Long-Term Metabolic Health As the use of GLP-1 medications continues to expand among adults in the…
Stuart Therapeutics Appoints David Jakeman as Chief Financial Officer to Support Late-Stage Development and Commercialization Plans Stuart Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing first-in-class collagen-reparative therapeutics for…
Ingenia Therapeutics Begins KOSDAQ Trading to Advance Vascular-Targeted Therapy Pipeline Ingenia Therapeutics, a clinical-stage biotechnology company focused on developing next-generation vascular-targeted therapies, has announced that its shares have begun trading…